BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17679185)

  • 1. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
    Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
    J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
    Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
    Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
    Quirk C; Gebauer K; De'Ambrosis B; Slade HB; Meng TC
    Cutis; 2010 Jun; 85(6):318-24. PubMed ID: 20666194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
    Sriprakash K; Godbolt A
    Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
    Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
    Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
    Warshauer E; Warshauer BL
    J Drugs Dermatol; 2008 May; 7(5):447-51. PubMed ID: 18505136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
    Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
    Tillman DK; Carroll MT
    J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
    Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
    J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
    Vun Y; Siller G
    Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
    Vidal D; Alomar A
    Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.